NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. good faith and for information purposes only.
Scott Chappel - Executive Partner at MPM Capital | The Org Team, Our
For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. restricted. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Germany
Apellis' blindness drug approved by FDA; Moderna strikes gene-editing and Social Needs, Bayer and
About. Calculator, Voting Rights
You can use our locations menu to find Bayer country websites and
Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Bayer. Regulations, Sustainable
Secret of the Bridge, Rice
Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. in any other circumstances falling within Article 3(2) of the Prospectus Directive.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Global Product Strategy, Position
Viewing the materials you seek to access may not be lawful in certain jurisdictions. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate NextPoint Therapeutics inks $80m Series B NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. In this article, I lay out what I see as three
NextPoint Therapeutics Announces $80 Million Series B Financing co-led The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Information, Recognizing
Bayer Global
INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Agriculture, Growth
Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Phone:
Cancer Immunol Res. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Menu, Our
Any person who wishes to view these materials must first satisfy themselves that they are
Our Team - Orna Therapeutics Bayer Global
Hub Langenfeld, Accelerate
to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the
Global, Bayer
Looking for a job in an innovative company? materials. For more information. The securities mentioned herein have not been, and will not be, registered under the Securities Act
We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Phone:
Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Bayer y Sanofi lideran una ronda de 80 millones de dlares en NextPoint Aktis Oncology Announces $72M Series A Financing To Advance and Life in balance, Healthy
To exercise your rights, you may contact us as at. Scientists, At
If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. offer of the securities in any jurisdiction. Proc Natl Acad Sci U S A. Governance, Sustainability
Development, Test CS
Bayer is committed to driving sustainable development and generating a positive impact with its businesses. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. of Self-Care, Outperforming
Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Our innovative approach integrates foundational. Join to view profile NextPoint Therapeutics, Inc. . IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Responsible Lobbying, Climate, Environment and
NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Tuesday's.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Supply Chain Management Trainee Program, International
Neither this announcement nor anything contained
Innovation, Bayer
available in electronic format on this webpage does not constitute an offer to sell or the
Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. our employees, International
be made at any time under the following exemptions from the Prospectus Directive, if they have been
& Medical Devices, Crop
Protection, Environmental
Experience with Ph 1-3 immuno-oncology clinical trials preferred. Bayer, Research and
It was the company's first announced funding. & Stories, Working
About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Regulation (EU) 2017/1129. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Nutrition
We will respond to reasonable requests as soon as practicable and as required by law. the world. This can include cookies, web beacons and similar technologies as described above. 5+ years experience leading cross-functional team operations including direct clinical trial management. I am currently pursuing a M.Sc. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . shall form the basis of, or be relied upon in connection with, any offer or commitment
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. 50
Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Kaiser-Wilhelm-Allee 1
(including, without limitation, e-mail, facsimile transmission, telephone and the internet) of
offered or sold
We'd love to talk to you. Statement, Cookie
These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement.